Business Wire

NY-THE-ROHATYN-GROUP

13.7.2022 14:02:12 CEST | Business Wire | Press release

Share
The Rohatyn Group Completes Acquisition of E-Bike Production Company, Leader From KJK Capital

The Rohatyn Group (“TRG”), a global asset management firm, today announced that it has completed the acquisition of electric bicycles (“e-bikes”) producer Leader 96 EOOD (“Leader” or the “Company”), from KJK Capital (“KJK”), establishing a partnership with Dimitar Zlatanov, the Company’s CEO and member of the founding family. TRG’s ownership can allow Leader to rapidly accelerate its e-bike production and broaden its product offering to address burgeoning demand from customers across Europe. Terms of the transaction were not disclosed.

Founded in 1996 in Plovdiv, Bulgaria, Leader is a leading producer of e-bikes in Europe with sales across the continent. The Company produces a broad range of e-bikes including touring, trekking, mountain, folding and gravel bike models. The Company is planning to launch a new e-cargo bike in 2023.

“Leader is a highly attractive business that provides a unique and high-quality product offering in the European e-bike sector. The Company is well-positioned to benefit from the continuing transformation of city transport infrastructures towards bicycle-friendly zones, increased demand for practical eco-friendly transportation and shared bike programs, as well as the growth of last-mile micro-delivery. Additionally, an increasing focus on healthier lifestyles means e-bikes can offer a highly democratic exercise solution across a wide spectrum of age and fitness levels,” said TRG’s Colin Clark, Partner and Head of EMEA Private Markets, and Stepan Karpukhin, Managing Director, who led the deal alongside Stanislav Bachvarov, Director.

“Leader is a high-growth business with an international profile that fits in perfectly with TRG’s global approach. We strongly believe that the Company has the potential to be a leading player in the e-bike sector thanks to its focus on customer service and forward-thinking approach to technology,” added Nick Rohatyn, CEO of TRG. “We believe increased adoption of e-bikes can contribute to societal progress towards more sustainable urban development, reduction of carbon emissions, and healthier lifestyles, and are proud to invest in a company that recognizes the significance of a positive environmental impact. We look forward to delivering strong growth alongside Dimitar and his team.”

Dimitar Zlatanov, CEO and member of the founding family, commented, “I am tremendously proud of the growth Leader has already achieved, as we have transformed our business into a leading e-bike producer in Europe. We look forward to continuing our growth in partnership with The Rohatyn Group and leveraging the team’s expertise.”

Kustaa Aima, Managing Partner at KJK Capital added “Leader is a great company that transformed through our period of ownership into a leading European e-bike producer. We wish both TRG and Dimitar Zlatanov all the best and look forward hearing more about the Company’s strong growth in the years ahead.”

About TRG

Founded in 2002, The Rohatyn Group is an asset management firm focused on emerging markets and real assets, headquartered in New York, with a global presence in 16 cities across the US, Latin America, Europe, the Middle East, India and Southeast Asia. For more information, please visit www.rohatyngroup.com

About KJK

Founded in 2010, KJK Capital is an independent, partner owned, private equity manager focused on European Frontier markets with a combined assets under management of EUR 600 million. With main offices in Helsinki, Vilnius and Luxembourg, KJK has also local representation in Estonia, Slovenia, Croatia, Bulgaria and Romania. For more information about KJK, please visit www.kjkcapital.com .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye